Price of ruxolitinib/ruxolitinib cream in China in 2025

Ruxolitinib is a topical drug that is a Janus kinase (JAK) inhibitor and is mainly used to treat some immune and inflammatory diseases, especially skin diseases such as atopic dermatitis (eczema). Atopic dermatitis is a chronic, recurring skin disease, usually accompanied by symptoms such as severe itching, redness, dryness, and cracking, which seriously affects the patient's quality of life. Ruxolitinib cream slows down the immune response and controls the inflammatory response of the skin by inhibiting the JAK pathway, thereby relieving symptoms.

As a topical treatment, the main advantage of ruxolitinib cream is its direct effect on the skin. Compared with oral drugs, it can act locally and reduce the impact on the whole body. Therefore, ruxolitinib cream has relatively few side effects and significant therapeutic effects, making it an important drug for the treatment of moderate to severe atopic dermatitis.

However, although ruxolitinib cream has been approved and put into use in some countries, it has not yet been officially launched in mainland China. Therefore, if patients want to use the drug, they usually need to purchase it through overseas channels. In foreign markets, ruxolitinib cream is available in both original and generic versions. The specification of the original drug is usually 1.5%*60g, and each box is sold for about 20,000 yuan (the specific price is affected by exchange rate fluctuations). This may be a high burden for most patients.

For price-sensitive patients, generic drugs from Bangladesh, India and other countries provide more economical options. The generic version of ruxolitinib cream has the same ingredients as the original drug, with similar efficacy and safety. The usual specification is 1.5%*30g, and each box sells for about more than 500 yuan. Because these generic drugs are relatively low-priced, they provide a viable alternative for patients who cannot afford the brand-name drugs.

Reference: https://www.opzelura.com/